Angiotensin converting enzyme inhibitors and alzheimer disease in the presence of the apolipoprotein e4 allele

American Journal of Geriatric Psychiatry

Volumn 22, Issue 2, 2014, Pages 177-185

  Qiu, Wendy Wei Qiao ^a,b   Lai, Angela ^a   Mon, Timothy ^a   Mwamburi, Mkaya ^c   Taylor, Warren ^d   Rosenzweig, James ^b   Kowall, Neil ^a   Stern, Robert ^a   Zhu, Haihao ^a   Steffens, David C ^e  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Alzheimer's Disease Center   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

ACE inhibitor; Alzheimer disease; Angiotensin converting enzyme (ACE); Apolipoprotein E4 allele (ApoE4)

Indexed keywords

APOLIPOPROTEIN E4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AFRICAN AMERICAN; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DNA DETERMINATION; ETHNICITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICATION COMPLIANCE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT EDUCATION; SEX; VERY ELDERLY;

ACE INHIBITOR; ALZHEIMER DISEASE; ANGIOTENSIN CONVERTING ENZYME (ACE); APOLIPOPROTEIN E4 ALLELE (APOE4);

AGED; ALLELES; ALZHEIMER DISEASE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; APOLIPOPROTEIN E4; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDYL-DIPEPTIDASE A;

EID: 84893648634     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2012.08.017     Document Type: Article

References (46)

1. Selkoe DJ: Biochemistry and molecular biology of amyloid betaprotein and the mechanism of Alzheimer's disease. Handb Clin Neurol 2008; 89:245-260
2. Hu J, Igarashi A, Kamata M, et al: Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 2001; 276:47863-47868
3. Qiu WQ, Folstein MF: Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 2006; 27:190-198
4. Zou K, Maeda T, Watanabe A, et al: Abeta42-to-Abeta40-and angiotensin-converting activities in different domains of angiotensinconverting enzyme. J Biol Chem 2009; 284:31914-31920
5. Leduc V, Jasmin-Belanger S, Poirier J: APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol Med 2010; 16: 469-477
6. Zlokovic BV: Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12:723-738
7. Bertram L: Alzheimer's disease genetics current status and future perspectives. Int Rev Neurobiol 2009; 84:167-184
8. Vardy ER, Rice PJ, Bowie PC, et al: Plasma angiotensin-converting enzyme in Alzheimer's disease. J Alzheimers Dis 2009; 16:609-618
9. Akatsu H, Ogawa N, Kanesaka T, et al: Higher activity of peripheral blood angiotensin-converting enzyme is associated with lateronset of Alzheimer's disease. J Neurol Sci 2011; 300:67-73
10. Burgess E: Reviewing the benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy-are they drug specific or class specific? Can J Cardiol 2010; 26(Suppl E):15Ee19E
11. Norris S, Weinstein J, Peterson K, et al: Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report. Portland (OR): Oregon Health & Science University 2010
12. Todd S, McGuinness B, Passmore AP: Designing appropriate clinical trials to assess ACEI use and cognitive decline in older adults with hypertension. Arch Intern Med 2010; 170:107
13. Anderson C, Teo K, Gao P, et al: Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011; 10:43-53
14. Sink KM, Leng X, Williamson J, et al: Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med 2009; 169:1195-1202
15. Shah K, Qureshi SU, Johnson M, et al: Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am J Geriatr Pharmacother 2009; 7:250-261
16. Davies NM, Kehoe PG, Ben-Shlomo Y, et al: Associations of antihypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis 2011; 26: 699-708
17. Zou K, Yamaguchi H, Akatsu H, et al: Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci 2007; 27:8628-8635
18. Eckman EA, Adams SK, Troendle FJ, et al: Regulation of steadystate beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 2006; 281:30471-30478
19. Hemming ML, Selkoe DJ, Farris W: Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis 2007; 26:273-281
20. Baehner FL, Lee M, Demeure MJ, et al: Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy. J Surg Oncol 2011; 103:563-573
21. Scott TM, Peter I, Tucker KL, et al: The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psychiatry 2006; 21:519-528
22. Qiu WQ, Sun X, Selkoe DJ, et al: Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 2007; 22:536-542
23. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
24. Petersen RC, Smith GE, Waring SC, et al: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308
25. Lahoz C, Osgood D, Wilson PW, et al: Frequency of phenotypegenotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem 1996; 42:1817-1823
26. Peila R, Rodriguez BL, Launer LJ: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002; 51:1256-1262
27. Strittmatter WJ, Saunders AM, Schmechel D, et al: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:1977-1981
28. Caselli RJ, Dueck AC, Locke DE, et al: Cerebrovascular risk factors and preclinical memory decline in healthy APOE epsilon4 homozygotes. Neurology 2011; 76:1078-1084
29. Tanzi RE, Bertram L: New frontiers in Alzheimer's disease genetics. Neuron 2001; 32:181-184
30. Hajjar I, Kritchevsky S, Newman AB, et al: Renin angiotensin system gene polymorphisms modify angiotensin-converting enzyme inhibitors' effect on cognitive function: the health, aging and body composition study. J Am Geriatr Soc 2010; 58: 1035-1042
31. Miners S, Ashby E, Baig S, et al: Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 2009; 1:163-177
32. Gearing M, Mori H, Mirra SS: Abeta-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 1996; 39: 395-399
33. Holtzman DM: In vivo effects of ApoE and clusterin on amyloidbeta metabolism and neuropathology. J Mol Neurosci 2004; 23: 247-254
34. Hemming ML, Selkoe DJ: Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 2005; 280:37644-37650
35. Todd S, McGuinness B, Passmore AP: Prevention of dementia by ACE inhibitors and angiotensin receptor blockers-potential but not proven. Int J Clin Pract 2010; 64:1595-1598
36. Killiany RJ, Gomez-Isla T, Moss M, et al: Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann Neurol 2000; 47:430-439
37. Jouquey S, Mathieu MN, Hamon G, et al: Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats. Neuropharmacology 1995; 34: 1689-1692
38. Tan J, Wang JM, Leenen FH: Inhibition of brain angiotensinconverting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats. Am J Hypertens 2005; 18:158-164
39. Ralat LA, Ren M, Schilling AB, et al: Protective role of Cys-178 against the inactivation and oligomerization of human insulindegrading enzyme by oxidation and nitrosylation. J Biol Chem 2009; 284:34005-34018
40. Liu Z, Zhu H, Fang GG, et al: Characterization of insulin degrading enzyme and other amyloid-beta degrading proteases in human serum: a role in Alzheimer's disease? J Alzheimers Dis 2012; 29: 329-340
41. Mawuenyega KG, Sigurdson W, Ovod V, et al: Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2011; 330:1774
42. Deane R, Wu Z, Sagare A, et al: LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43:333-344
43. Mayeux R, Tang MX, Jacobs DM, et al: Plasma amyloid betapeptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999; 46:412-416
44. Graff-Radford NR, Crook JE, Lucas J, et al: Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64:354-362
45. Yamada K, Uchida S, Takahashi S, et al: Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer's disease. Brain Res 2010; 1352:176-186
46. Klunk WE, Engler H, Nordberg A, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319